ACHIEVING THERAPEUTIC GOAL ON LDL IN HIGH AND VERY HIGH RISK PATIENTS IN A DEDICATED OUTPATIENT CLINIC

Abstract

Listen

Translate article

Objective: High LDL cholesterol levels represent an important risk factor for development of cardiovascular disease. The reduction of LDL reduces cardiovascular risk. Current guidelines (ESC 2019) recommend ambitious LDL levels for high and very high risk patients. But, in clinical practice, just a part of these patients achieve the ESC 2019 goals (DA VINCI Study). Design and method: We evaluated, in the first 152 patients, at high and very high cardiovascular risk, consecutively afferent to our dedicated clinic for hyperlipidaemia (Lipid Center CS), the achievement of the therapeutic goal of LDL according to ESC 2019 guidelines. All patients were on lipid-lowering drug treatment from at least twelve months and the last blood tests were no less recent than three months. Results: Of all patients, 82 were female. The mean age was 65.24 ± 10.33 years. Thirty patients were in secondary prevention. Of all patients, 70% reached the therapeutic goal (77% with very high risk and 68% with high risk). Fifty nine% were taking high-intensity lipid-lowering therapy. Seventy one% were taking combination therapy. Thirty four% were treated with PCSK9 inhibitors. Conclusions: Taking note of the limited number of the sample, our therapeutic achieved results are higher than that got in the DA VINCI study in which only 60% of patients, from west Europe, reached the therapeutic goal. A dedicated clinic for hyerlipidaemia and the high use of combination therapy with intensive drugs and extensive use of PCSK9 inhibitors may justify the results of our study. Our center did not participated in the DA VINCI study.